BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 37434173)

  • 1. Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy.
    Yang X; Zheng M; Ning Y; Sun J; Yu Y; Zhang S
    J Transl Med; 2023 Jul; 21(1):456. PubMed ID: 37434173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
    Li Q; Xiao X; Feng J; Yan R; Xi J
    Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Yang M; Xie X; Ding Y
    Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and Investigation of an LINC00284-Associated Regulatory Network in Serous Ovarian Carcinoma.
    Wang S; Zhang L; Tao L; Pang L; Fu R; Fu Y; Liang W; Ding Y; Jia W
    Dis Markers; 2020; 2020():9696285. PubMed ID: 32076467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
    Zhan F; Guo Y; He L
    J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of immunity- and ferroptosis-related genes for predicting the prognosis of serous ovarian cancer.
    Yuan X; Zhou Q; Zhang F; Zheng W; Liu H; Chen A; Tao Y
    Gene; 2022 Sep; 838():146701. PubMed ID: 35777713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four Types of RNA Modification Writer-Related lncRNAs Are Effective Predictors of Prognosis and Immunotherapy Response in Serous Ovarian Carcinoma.
    Ye L; Pan K; Fang S; Wu SN; Chen S; Tang S; Wang N; Zhang H; Tong X; Shi X; Feng S; Xiang D; Zou R; Hu Y; Xue X; Guo G
    Front Immunol; 2022; 13():863484. PubMed ID: 35585970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of MMP17 predicts poor clinical outcomes in epithelial ovarian cancer patients.
    Xiao C; Wang Y; Cheng Q; Fan Y
    Medicine (Baltimore); 2022 Aug; 101(34):e30279. PubMed ID: 36042626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
    Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
    Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer.
    Li YL; Ye F; Cheng XD; Hu Y; Zhou CY; Lü WG; Xie X
    Eur J Cancer; 2010 Jul; 46(11):2104-18. PubMed ID: 20547056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of Epithelial Splicing Regulatory Protein 1 in Metastatic Lesions of Serous Ovarian Carcinoma Correlates with Poor Patient Prognosis.
    Lu X; Li R; Wang X; Guo Q; Wang L; Zhou X
    Cancer Biother Radiopharm; 2022 Nov; 37(9):850-861. PubMed ID: 34495766
    [No Abstract]   [Full Text] [Related]  

  • 14. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
    Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
    Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and validation of molecular subtype and signature of immune cell-related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients.
    Ling L; Li B; Wu H; Zhang K; Li S; Ke B; Zhu Z; Liu T; Liu P; Zhang B
    J Gene Med; 2024 Jan; 26(1):e3606. PubMed ID: 38282157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma.
    Hwang C; Lee HJ; Na JY; Kim KH; Song YJ; Kim JY; Kim K; Shin DH; Park JY; Kim SY; Lee JH; Choi KU
    J Ovarian Res; 2023 Jan; 16(1):3. PubMed ID: 36609273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a novel transcription factors-related prognostic signature for serous ovarian cancer.
    Li H; Wu N; Liu ZY; Chen YC; Cheng Q; Wang J
    Sci Rep; 2021 Mar; 11(1):7207. PubMed ID: 33785763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
    Kar SP; Adler E; Tyrer J; Hazelett D; Anton-Culver H; Bandera EV; Beckmann MW; Berchuck A; Bogdanova N; Brinton L; Butzow R; Campbell I; Carty K; Chang-Claude J; Cook LS; Cramer DW; Cunningham JM; Dansonka-Mieszkowska A; Doherty JA; Dörk T; Dürst M; Eccles D; Fasching PA; Flanagan J; Gentry-Maharaj A; Glasspool R; Goode EL; Goodman MT; Gronwald J; Heitz F; Hildebrandt MA; Høgdall E; Høgdall CK; Huntsman DG; Jensen A; Karlan BY; Kelemen LE; Kiemeney LA; Kjaer SK; Kupryjanczyk J; Lambrechts D; Levine DA; Li Q; Lissowska J; Lu KH; Lubiński J; Massuger LF; McGuire V; McNeish I; Menon U; Modugno F; Monteiro AN; Moysich KB; Ness RB; Nevanlinna H; Paul J; Pearce CL; Pejovic T; Permuth JB; Phelan C; Pike MC; Poole EM; Ramus SJ; Risch HA; Rossing MA; Salvesen HB; Schildkraut JM; Sellers TA; Sherman M; Siddiqui N; Sieh W; Song H; Southey M; Terry KL; Tworoger SS; Walsh C; Wentzensen N; Whittemore AS; Wu AH; Yang H; Zheng W; Ziogas A; Freedman ML; Gayther SA; Pharoah PD; Lawrenson K
    Br J Cancer; 2017 Feb; 116(4):524-535. PubMed ID: 28103614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long Non-coding RNA
    Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT
    Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.